The EBMT/EHA CAR-T Cell Handbook

1. Introduction N Kröger, J Gribben, C Chabannon, H Einsele, I Yakoub-Agha2. The science behind CAR-T CellsJ Gribben.2. Structure of and signaling through the Chimeric Antigen Receptor 3. Genetic engineering of autologous or allogeneic immune effector cells 4. What defines a good tumor antigen? Minimizing or managing on target / off tumor and off target / off tumor effects 5. Mechanisms of resistance to CAR-T 6. The European landscape for preclinical and early clinical research Chapter 3. Manufacturing CAR-T Cells: the supply chain.C Chabannon. 7. Providing the starting material to the manufacturer of an approved and commercially available autologous CAR-T Cell treatment 8. Receiving, handling, storage, distribution, thawing and administration of the Gene Therapy Medicinal Product (GTMP) shipped from the manufacturing facility 9. Point-of-Care (POC) manufacturing of autologous CAR-T Cells 10. Off-the shelf allogeneic CAR-T Cells or other Immune Effector Cells (IECs) for the future 4. Clinical indications for CAR-T Cells. H Einsele.11. Pediatric Acute Lymphoblastic Leukemia (ALL) 12. Adult Acute Lymphoblastic Leukemia (ALL) 13. Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma14. Mantle Cell Lymphoma 15. Chronic Lymphocytic Leukemia 16 Indolent lymphomas 17. Multiple Myeloma 18. Developments in other hematological malignanciesi. Other lymphoid malignanciesii. Myeloid Malignancies i. Developments in solid tumors 5. Clinical management of patients treated with CAR-T Cells. I Yakoub-Agha.19. Bridging chemotherapy/ general chapteri. Adult ALL ii. Pediatric and young adult ALLiii. DLBCL, FL and indolent lymphomas iv. Multiple myeloma 20. Lymphodepleting Conditioning Regimens 21. Management of Cytokine Release Syndrome (CRS) 22. Management of Immune effector Cells Associated Neurotoxicity Syndrome (ICANS)23. Management of hypogammaglobulinemia and B-cell aplasia 24. Management of myelotoxicity(aplasia) and infectious complications 25. Management of other

Nicolaus Kröger MD, is the current EBMT President, Professor of Medicine and Medical Director of the Department of Stem Cell Transplantation at the University Medical Center, Hamburg - Eppendorf, Germany 

John G. Gribben, MD DSc FRCP FRCPath, FMedSci, is the Past President of EHA, Professor of Medical Oncology and Director of Stem Cell Transplantation at Saint Bartholomew's Hospital, Queen Mary School of Medicine, University of London, UK

Christian Chabannon, MD, PhD, is the current chair of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT, is the Head and Qualified Person of the Cell Collection and Cell Processing Facility at Institut Paoli-Calmettes, the Coordinator of the "Centre d'Investigations Cliniques en Biothérapies de Marseille", and a Professor of Cell Biology at Aix-Marseille University, France

Ibrahim Yakoub-Agha, MD, PhD, is the current chair of the Chronic Malignancies Working Party of the EBMT and holds the position of coordinating professor for the Department of Hematology at Lille Faculty of Medicine, France

Hermann Einsele, MD, FRCP, is Full Professor of Internal Medicine and has been Director of the Department of Internal Medicine II of the University Hospital Würzburg, Germany